Last reviewed · How we verify
Ro 205720 (CARPROFEN)
Carprofen, marketed by Roche, is a nonsteroidal anti-inflammatory drug (NSAID) that blocks prostaglandin production to alleviate pain and inflammation, currently holding a significant market position. Its key strength lies in its well-established mechanism and broad therapeutic use, supported by a key composition patent expiring in 2028. The primary risk is the competitive landscape, with multiple same-target drugs such as aceclofenac, acetylsalicylic acid, balsalazide, benzquinamide, and bromfenac, some of which are patent-protected until 2031 and 2032.
At a glance
| Generic name | CARPROFEN |
|---|---|
| Sponsor | Roche |
| Drug class | carprofen |
| Target | Complement C5, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1987 |
Approved indications
Common side effects
- Bilirubinuria
- Ketonuria
- SAP increase
- ALT increase
- Vomiting
- Diarrhea/Soft stool
- BUN increase
- Diarrhea
- AST increase
- Ocular disease
- Dermatitis/Skin lesion
- Vomiting
Serious adverse events
- Acute hepatic toxicity
- Gastrointestinal ulceration
- Gastrointestinal bleeding
- Acute renal failure
- Immune-mediated hemolytic anemia
- Immune-mediated thrombocytopenia
- Pancreatitis
- Hematemesis
- Melena
- Death
Key clinical trials
- NovoX®Cup as Primary Dressing After Breast Reduction
- Effects of the Application of a Hyper-oxygenated Gel After Oral Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |